{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:54:48Z","timestamp":1778219688912,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00415-023-11872-2","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T16:02:02Z","timestamp":1689782522000},"page":"5436-5448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9594-9336","authenticated-orcid":false,"given":"Fabrizio","family":"Vernieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Guerzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi Francesco","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Schiano di Cola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Ornello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Cevoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Lovati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Perrotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Cetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio Soeren","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Taranta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierangelo","family":"Geppetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"11872_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update. J Headache Pain 23:67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"key":"11872_CR2","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1177\/0333102419854082","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Goadsby PJ, Reuter U et al (2019) Long-term safety and tolerability of erenumab: three-plus year results from a 5-year open-label extension study in episodic migraine. Cephalalgia 39:1455\u20131464. https:\/\/doi.org\/10.1177\/0333102419854082","journal-title":"Cephalalgia"},{"key":"11872_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2059975","author":"P Pozo-Rosich","year":"2022","unstructured":"Pozo-Rosich P, Detke HC, Wang S et al (2022) Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin. https:\/\/doi.org\/10.1080\/03007995.2022.2059975","journal-title":"Curr Med Res Opin"},{"key":"11872_CR4","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ENE.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28:1716\u20131725. https:\/\/doi.org\/10.1111\/ENE.14715","journal-title":"Eur J Neurol"},{"key":"11872_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/0333102421989601","volume":"41","author":"K Drellia","year":"2021","unstructured":"Drellia K, Kokoti L, Deligianni CI et al (2021) Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. Cephalalgia 41:851\u2013864. https:\/\/doi.org\/10.1177\/0333102421989601","journal-title":"Cephalalgia"},{"key":"11872_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01335-2","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A et al (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. https:\/\/doi.org\/10.1186\/s10194-021-01335-2","journal-title":"J Headache Pain"},{"key":"11872_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Ehrlich M, Gendolla A et al (2022) Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 42:108\u2013118. https:\/\/doi.org\/10.1177\/03331024211053571","journal-title":"Cephalalgia"},{"key":"11872_CR8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF et al (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35:478\u2013488. https:\/\/doi.org\/10.1177\/0333102414547138","journal-title":"Cephalalgia"},{"key":"11872_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0951-2","author":"S F\u00f6rderreuther","year":"2018","unstructured":"F\u00f6rderreuther S, Zhang Q, Stauffer VL et al (2018) Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain. https:\/\/doi.org\/10.1186\/s10194-018-0951-2","journal-title":"J Headache Pain"},{"key":"11872_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Altamura C, Brunelli N et al (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22:35. https:\/\/doi.org\/10.1186\/s10194-021-01247-1","journal-title":"J Headache Pain"},{"key":"11872_CR11","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Cevoli S et al (2021) Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache 61:1351\u20131363. https:\/\/doi.org\/10.1111\/head.14194","journal-title":"Headache"},{"key":"11872_CR12","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/ENE.15563","volume":"30","author":"F Vernieri","year":"2023","unstructured":"Vernieri F, Brunelli N, Marcosano M et al (2023) Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: the multicenter prospective cohort GARLIT study. Eur J Neurol 30:224\u2013234. https:\/\/doi.org\/10.1111\/ENE.15563","journal-title":"Eur J Neurol"},{"key":"11872_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano D, Lipton RB, Scher AI et al (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 18:101. https:\/\/doi.org\/10.1186\/s10194-017-0787-1","journal-title":"J Headache Pain"},{"key":"11872_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211014616","author":"AR Gantenbein","year":"2021","unstructured":"Gantenbein AR, Agosti R, Gobbi C et al (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment\u2014a real-life cohort study. Cephalalgia. https:\/\/doi.org\/10.1177\/03331024211014616","journal-title":"Cephalalgia"},{"key":"11872_CR15","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1007\/s10072-020-05022-z","volume":"42","author":"E De Matteis","year":"2021","unstructured":"De Matteis E, Affaitati G, Frattale I et al (2021) Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci 42:3297\u20133303. https:\/\/doi.org\/10.1007\/s10072-020-05022-z","journal-title":"Neurol Sci"},{"key":"11872_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211046617","author":"B Raffaelli","year":"2021","unstructured":"Raffaelli B, Terhart M, Overeem LH et al (2021) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia. https:\/\/doi.org\/10.1177\/03331024211046617","journal-title":"Cephalalgia"},{"key":"11872_CR17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Brunelli N, Messina R et al (2021) Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain 22:154. https:\/\/doi.org\/10.1186\/s10194-021-01363-y","journal-title":"J Headache Pain"},{"key":"11872_CR18","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/ENE.15260","volume":"29","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S et al (2022) Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol 29:1505\u20131513. https:\/\/doi.org\/10.1111\/ENE.15260","journal-title":"Eur J Neurol"},{"key":"11872_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/S10194-022-01417-9","author":"B Raffaelli","year":"2022","unstructured":"Raffaelli B, Terhart M, Mecklenburg J et al (2022) Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience. J Headache Pain. https:\/\/doi.org\/10.1186\/S10194-022-01417-9","journal-title":"J Headache Pain"},{"key":"11872_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International classification of headache disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"key":"11872_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20:6. https:\/\/doi.org\/10.1186\/s10194-018-0955-y","journal-title":"J Headache Pain"},{"key":"11872_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/S10194-022-01408-W","volume":"23","author":"R Ornello","year":"2022","unstructured":"Ornello R, Baraldi C, Guerzoni S et al (2022) Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. J Headache Pain 23:38. https:\/\/doi.org\/10.1186\/S10194-022-01408-W","journal-title":"J Headache Pain"},{"key":"11872_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s10194-022-01538-1","volume":"24","author":"TP Do","year":"2023","unstructured":"Do TP, Hougaard A, Dussor G et al (2023) Migraine attacks are of peripheral origin: the debate goes on. J Headache Pain 24:3. https:\/\/doi.org\/10.1186\/s10194-022-01538-1","journal-title":"J Headache Pain"},{"key":"11872_CR24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, DiN K (2018) CGRP as the target of new migraine therapies\u2014successful translation from bench to clinic. Nat Rev Neurol 14:338\u2013350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1","journal-title":"Nat Rev Neurol"},{"key":"11872_CR25","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/head.13843","volume":"60","author":"L Pellesi","year":"2020","unstructured":"Pellesi L, Do TP, Ashina H et al (2020) Review articles dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: Is there a rationale? Headache. Headache 60:1056\u20131065. https:\/\/doi.org\/10.1111\/head.13843","journal-title":"Headache"},{"key":"11872_CR26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","volume":"10","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, Frishberg BM, Schim JD et al (2021) Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to OnabotulinumtoxinA: a retrospective chart review. Pain Ther 10:809\u2013826. https:\/\/doi.org\/10.1007\/s40122-021-00264-x","journal-title":"Pain Ther"},{"key":"11872_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-022-28204-Z","author":"F De Logu","year":"2022","unstructured":"De Logu F, Nassini R, Hegron A et al (2022) Schwann cell endosome CGRP signals elicit periorbital mechanical allodynia in mice. Nat Commun. https:\/\/doi.org\/10.1038\/S41467-022-28204-Z","journal-title":"Nat Commun"},{"key":"11872_CR28","doi-asserted-by":"publisher","first-page":"e2121","DOI":"10.1212\/WNL.0000000000008944","volume":"94","author":"K Mullin","year":"2020","unstructured":"Mullin K, Kudrow D, Croop R et al (2020) Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology 94:e2121\u2013e2125. https:\/\/doi.org\/10.1212\/WNL.0000000000008944","journal-title":"Neurology"},{"key":"11872_CR29","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/head.13635","volume":"59","author":"P Barbanti","year":"2019","unstructured":"Barbanti P, Egeo G, Mitsikostas DD (2019) Trigeminal-targeted treatments in migraine: Is 60% the magic number? Headache 59:1659\u20131661. https:\/\/doi.org\/10.1111\/head.13635","journal-title":"Headache"},{"key":"11872_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/TOXINS15010076","volume":"15","author":"G Sebastianelli","year":"2023","unstructured":"Sebastianelli G, Casillo F, Di Renzo A et al (2023) Effects of botulinum toxin Type A on the nociceptive and lemniscal somatosensory systems in chronic migraine: an electrophysiological study. Toxins (Basel) 15:76. https:\/\/doi.org\/10.3390\/TOXINS15010076","journal-title":"Toxins (Basel)"},{"key":"11872_CR31","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1177\/03331024221103811","volume":"42","author":"F Casillo","year":"2022","unstructured":"Casillo F, Sebastianelli G, Di Renzo A et al (2022) The monoclonal CGRP-receptor blocking antibody erenumab has different effects on brainstem and cortical sensory-evoked responses. Cephalalgia 42:1236\u20131245. https:\/\/doi.org\/10.1177\/03331024221103811","journal-title":"Cephalalgia"},{"key":"11872_CR32","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/HEAD.14139","volume":"61","author":"L Grazzi","year":"2021","unstructured":"Grazzi L, Andrasik F, Rizzoli P et al (2021) Acceptance and commitment therapy for high frequency episodic migraine without aura: Findings from a randomized pilot investigation. Headache 61:895\u2013905. https:\/\/doi.org\/10.1111\/HEAD.14139","journal-title":"Headache"},{"key":"11872_CR33","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1111\/BCP.14096","volume":"85","author":"JB Fiedler-Kelly","year":"2019","unstructured":"Fiedler-Kelly JB, Cohen-Barak O, Morris DN et al (2019) Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine. Br J Clin Pharmacol 85:2721\u20132733. https:\/\/doi.org\/10.1111\/BCP.14096","journal-title":"Br J Clin Pharmacol"},{"key":"11872_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jcph.1511","volume":"60","author":"W Kielbasa","year":"2020","unstructured":"Kielbasa W, Quinlan T (2020) Population pharmacokinetics of galcanezumab, an anti-CGRP antibody, following subcutaneous dosing to healthy individuals and patients with migraine. J Clin Pharmacol 60:229\u2013239. https:\/\/doi.org\/10.1002\/jcph.1511","journal-title":"J Clin Pharmacol"},{"key":"11872_CR35","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/CPT.799","volume":"103","author":"J de Hoon","year":"2018","unstructured":"de Hoon J, Van Hecken A, Vandermeulen C et al (2018) Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther 103:815\u2013825. https:\/\/doi.org\/10.1002\/CPT.799","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11872-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11872-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11872-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T09:04:42Z","timestamp":1697274282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11872-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["11872"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11872-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"7 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fabrizio Vernieri received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Allergan\/Abbvie, Amgen, Angelini, Lilly, Lundbeck, Novartis, and Teva. Simona Guerzoni received honoraria and fees from Allergan\/Abbvie, Lilly, Lundbeck, Teva, Novartis and Pfizer. Luigi Francesco Iannone received personal fees from Lilly and Teva and travel grants from Lundbeck. Carlo Baraldi received honoraria and fees from Allergan, Lilly, Lundbeck, Teva and Novartis. Renata Rao received honoraria for travel grants, honoraria for advisory boards, speaker panels from Novartis, Lillly, Teva, Allergan, Lundbeck. Francesca Schiano di Cola received speaker honoraria from Lilly, Lundbeck and Novartis. Sabina Cevoli received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Novartis, Teva, Lilly, Allergan, Ibsa, Amgen and Lundbeck. Raffaele Ornello reports speaker fees from Novartis and Lilly, travel grants from Teva, and support for publication from Novartis and Allergan. Carlo Lovati received grants from Novartis and Lilly. Maria Albanese has been a consultant and member of Advisory Board for Novartis, Teva, Lundbeck, Lilly, Allergan\/Abbvie; has received funding for travel and speaker honoraria from Lusofarmaco, Angelini, Novartis, Lilly, Teva, Merck-Serono. Armando Perrotta received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Allergan, Lilly, Novartis, and Teva. Ilaria Cetta reports personal fees from Lilly for speaker activities. Massimo Filippi is Editor-in-Chief of the Journal of Neurology and Associate Editor of Neurological Sciences, received compensation for consulting services and\/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Teva Pharmaceutical Industries, Roche, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). Pierangelo Geppetti received personal fees from Allergan, Lilly, Novartis, Amgen, TEVA; grants from Amgen, TEVA, Eli-Lilly, Allergan, Chiesi; Scientific Advisory Board, Endosome Therapeutics; Founding scientist of FloNext srl, Spinoff of the University of Florence. Simona Sacco reports personal fees from Allergan-AbbVie, AstraZeneca, Abbott, Teva, Novartis, Novo Nordisk, Medscape, Neurodiem and Eli Lilly. Claudia Altamura received travel grants and honoraria from Novartis, Lilly, Lusofarmaco, Laborest, Abbvie-Allergan, Almirall. Nicoletta Brunelli, Sergio Soeren Rossi and Valentina Taranta have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Informed consent was obtained from patients for collecting anonymously clinical and demographics data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard statement"}}]}}